Storia in 8 fonti

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

The FDA has approved a first-in-class therapy for the treatment of erythrocytosis for adults with polycythemia vera. Rusfertide (Mimrylo; Protagonist Therapeutics, Takeda) received approval for adults who have been unable to achieve adequate control with other therapies.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo11 g fa

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

originale

Timeline cronologica

venerdì 28 agosto 2026·endpoints.news
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
venerdì 28 agosto 2026·morningstar.com
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

Confronto fonti

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

Timeline cronologica

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment…

FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

FDA approves Protagonist and Takeda’s drug for rare blood cancer

Mimrylo snags FDA approval for first-of-its-kind polycythemia vera treatment

FDA OKs Takeda, Protagonist drug for rare blood cancer

First-in-Class Drug Wins FDA Approval for Polycythemia Vera

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)